<DOC>
	<DOCNO>NCT00005984</DOCNO>
	<brief_summary>RATIONALE : Giving colony-stimulating factor , G-CSF , cyclophosphamide help stem cell move patient 's bone marrow blood collect store . Chemotherapy radiation therapy give prepare bone marrow stem cell transplant . The stem cell return patient replace blood-forming cell destroy chemotherapy radiation therapy . PURPOSE : This phase II trial study well cyclophosphamide plus filgrastim followed stem cell transplant work treat patient chronic phase accelerate phase chronic myelogenous leukemia .</brief_summary>
	<brief_title>Cyclophosphamide Filgrastim Followed By SCT Patients With Chronic Accelerated Phase Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Assess clinical outcome , survival , morbidity patient chronic accelerated phase chronic myelogenous leukemia treat cyclophosphamide filgrastim ( G-CSF ) follow autologous peripheral blood stem cell transplantation . - Determine whether prim cyclophosphamide filgrastim ( G-CSF ) increase fraction benign Philadelphia chromosome negative hematopoietic progenitor peripheral blood stem cell ( PBSC ) reduce incidence persistent recurrent leukemia autologous transplantation mobilize PBSC patient . OUTLINE : Patients receive prim therapy consist cyclophosphamide IV 2 hour day 1 filgrastim ( G-CSF ) daily subcutaneously ( SQ ) start day 5 continue completion leukapheresis . Peripheral blood stem cell ( PBSC ) collect day 14-21 . Patients receive preparative therapy transplant consist cyclophosphamide IV 2 hour day -7 -6 total body irradiation twice day day -4 -1 . Patients receive PBSC transplantation day 0 . Patients also receive G-CSF IV start day 0 continue blood count recover . Patients receive interferon alfa SQ daily absence unacceptable toxicity disease progression . Patients follow 3 week ; 3 , 6 , 9 , 12 , 18 month ; annually 5 year . PROJECTED ACCRUAL : Not specify</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Histologically confirm chronic accelerate phase chronic myelogenous leukemia ( CML ) Philadelphia chromosome positive OR BCR/ABL rearrangement Ineligible refuse participate ongoing allogeneic marrow donor transplant protocols 70 Performance status : Age 6570 year : Karnofsky 80100 % Under 65 year : Karnofsky 90100 % Renal : Age 6570 year : Creatinine clearance great 60 mL/min ( creatinine least 1.5 mg/dL ) Under 65 year : Not specify Cardiovascular : Age 6570 year : LVEF least 45 % Pulmonary : Age 6570 year : If history smoking respiratory symptom , spirometry DLCO must great 50 % predict Normal organ function ( exclude bone marrow ) Blast crisis post blast crisis Severe fibrosis define bilateral trephine biopsy Splenomegaly ( umbilicus ) respond chemotherapy and/or radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>chronic phase myelogenous leukemia</keyword>
	<keyword>accelerated phase myelogenous leukemia</keyword>
</DOC>